<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575753</url>
  </required_header>
  <id_info>
    <org_study_id>Resolvin-delirium</org_study_id>
    <nct_id>NCT04575753</nct_id>
  </id_info>
  <brief_title>Evaluating the Role of Pre-existing Resolvins in the Resolution of ICU Delirium</brief_title>
  <official_title>Evaluating the Role of Pre-existing Resolvins in the Resolution of ICU Delirium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Libre de Bruxelles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHU de Charleroi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université Libre de Bruxelles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As patient management is improving, more and more ICU survivors are being confronted with&#xD;
      cognitive dysfunction and this well after their hospital stay.&#xD;
&#xD;
      In the ICU, delirium rates have been reported to be as high at 81%. Delirium is associated&#xD;
      with patient and family stress, increased hospital costs, increased duration of stay,&#xD;
      escalation of care and increased mortality and morbidity.&#xD;
&#xD;
      The physiopathology of ICU cognitive impairment is complex and involves an inflammatory&#xD;
      cascade Recently, the role of 'resolvins' derived from omega-3 fatty acids has been studied&#xD;
      in the resolution of inflammation.&#xD;
&#xD;
      Therefore, this hypothesis of this study is that ICU patients with higher serum levels of&#xD;
      resolvins at ICU admission, ICU day 2 and day 5 will have a lesser degree of cognitive&#xD;
      impairment on day 5 of ICU stay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As patient management is improving, more and more ICU survivors are being confronted with&#xD;
      cognitive dysfunction and this well after their hospital stay.&#xD;
&#xD;
      Delirium is characterized by an acute onset or fluctuating course, inattention and either&#xD;
      disorganized thought (manifesting as memory, language and orientation difficulties) or&#xD;
      altered level of consciousness. Multiple forms exist: hyperactive versus hypoactive versus&#xD;
      mixed.&#xD;
&#xD;
      In the ICU, delirium rates have been reported to be as high at 81%. Delirium is associated&#xD;
      with patient and family stress, increased hospital costs, increased duration of stay,&#xD;
      escalation of care and increased mortality and morbidity.&#xD;
&#xD;
      The physiopathology of ICU cognitive impairment is complex. One theory is that, during&#xD;
      infection/trauma, the alarmin high molecular group box 1 (HMGB1) is released into the&#xD;
      bloodstream by activated platelets.&#xD;
&#xD;
      This damage-associated molecular pattern (DAMP) can bind to pattern recognition receptors on&#xD;
      circulating bone marrow-derived monocytes (BM-DMs), causing a platelet-monocyte interaction&#xD;
      but also triggering the nuclear translocation of the transcription factor NF-kappaB which&#xD;
      activates gene expression and release of pro-inflammatory cytokines. The onset of this&#xD;
      inflammatory state disrupts the blood brain barrier.&#xD;
&#xD;
      Within the brain parenchyma the chemokine MCP-1 and, by signaling through its receptor, CCR2,&#xD;
      attracts the BM-DMs. The influx of BM-DMs activates the resident quiescent microglia.&#xD;
      Together, BM-DMs and activated microglia release HMGB1, IL-6, and IL-1β ; thereby disrupting&#xD;
      long-term potentiation and the synaptic plasticity involved in cognitive functions of&#xD;
      learning and memory.&#xD;
&#xD;
      Inability to successfully resolve the inflammatory cascade promotes the development of&#xD;
      cognitive impairment.&#xD;
&#xD;
      Recently, the role of 'resolvins' derived from omega-3 fatty acids has been studied in the&#xD;
      resolution of inflammation.&#xD;
&#xD;
      In a mouse model of perioperative neurocognitive disorder, maresin 1 (a metabolite of&#xD;
      omega-3) improved post-operative cognition and prevented surgery-induced glial activation and&#xD;
      opening of the blood brain barrier. Similarly, in the same model, aspirine-triggered&#xD;
      resolving D1 improved post-operative cognition, reduced systemic IL-6 levels and reserved&#xD;
      surgery-induced astrogliosis.&#xD;
&#xD;
      Mechanically ventilated ICU patients who benefitted from omega-3 supplements, had a lesser&#xD;
      degree of ICU delirium.&#xD;
&#xD;
      Therefore, the hypothesis of this study is that ICU patients with higher serum levels of&#xD;
      resolvins at ICU admission, ICU day 2 and day 5 will have a lesser degree of cognitive&#xD;
      impairment on day 5 of ICU stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The influence of serum levels of resolvins (RvD1) at ICU admission, and ICU day 2 and day 5 on cognitive impairment (defined by CAM-ICU) on day 5 of ICU stay.</measure>
    <time_frame>5 days</time_frame>
    <description>Blood samples will be drawn at the day of ICU admission, day 2 and day 5 after ICU admission to measure resolvins (RvD1; 17SHDHA; DHA) through mass spectrometry.&#xD;
At the same timepoints, cognitive testing will be performed (CAM-ICU) to determine the presence or absence of delirium on day 5 of ICU admission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The influence of serum levels of resolvins (DHA) at ICU admission, and ICU day 2 and day 5 on cognitive impairment (defined by CAM-ICU) on day 5 of ICU stay.</measure>
    <time_frame>5 days</time_frame>
    <description>Blood samples will be drawn at the day of ICU admission, day 2 and day 5 after ICU admission to measure resolvins (RvD1; 17SHDHA; DHA) through mass spectrometry.&#xD;
At the same timepoints, cognitive testing will be performed (CAM-ICU) to determine the presence or absence of delirium on day 5 of ICU admission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The influence of serum levels of resolvins (17SHDHA)) at ICU admission, and ICU day 2 and day 5 on cognitive impairment (defined by CAM-ICU) on day 5 of ICU stay.</measure>
    <time_frame>5 days</time_frame>
    <description>Blood samples will be drawn at the day of ICU admission, day 2 and day 5 after ICU admission to measure resolvins (RvD1; 17SHDHA; DHA) through mass spectrometry.&#xD;
At the same timepoints, cognitive testing will be performed (CAM-ICU) to determine the presence or absence of delirium on day 5 of ICU admission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day0</measure>
    <time_frame>1 day</time_frame>
    <description>The influence of serum levels of CRP (at ICU admission) on cognitive impairment (defined by CAM-ICU) at ICU admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day0</measure>
    <time_frame>1 day</time_frame>
    <description>The influence of serum levels of TNF-alpha (at ICU admission) on cognitive impairment (defined by CAM-ICU) at ICU admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day0</measure>
    <time_frame>1 day</time_frame>
    <description>The influence of serum levels of HMGB1 (at ICU admission) on cognitive impairment (defined by CAM-ICU) at ICU admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day0</measure>
    <time_frame>1 day</time_frame>
    <description>The influence of serum levels of PF4 (at ICU admission) on cognitive impairment (defined by CAM-ICU) at ICU admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day0</measure>
    <time_frame>1 day</time_frame>
    <description>The influence of serum levels of lactate (at ICU admission) on cognitive impairment (defined by CAM-ICU) at ICU admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day2</measure>
    <time_frame>2 days</time_frame>
    <description>The influence of serum levels of CRP (at ICU admission) on cognitive impairment (defined by CAM-ICU) on ICU day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day2</measure>
    <time_frame>2 days</time_frame>
    <description>The influence of serum levels of TNF-alpha (at ICU admission) on cognitive impairment (defined by CAM-ICU) on ICU day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day2</measure>
    <time_frame>2 days</time_frame>
    <description>The influence of serum levels of HMGB1 (at ICU admission) on cognitive impairment (defined by CAM-ICU) on ICU day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day2</measure>
    <time_frame>2 days</time_frame>
    <description>The influence of serum levels of PF4 (at ICU admission) on cognitive impairment (defined by CAM-ICU) on ICU day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day2</measure>
    <time_frame>2 days</time_frame>
    <description>The influence of serum levels of lactate (at ICU admission) on cognitive impairment (defined by CAM-ICU) on ICU day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day5</measure>
    <time_frame>5 days</time_frame>
    <description>The influence of serum levels of CRP (at ICU admission) on cognitive impairment (defined by CAM-ICU) on ICU day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day5</measure>
    <time_frame>5 days</time_frame>
    <description>The influence of serum levels of TNF-alpha (at ICU admission) on cognitive impairment (defined by CAM-ICU) on ICU day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day5</measure>
    <time_frame>5 days</time_frame>
    <description>The influence of serum levels of HMGB1 (at ICU admission) on cognitive impairment (defined by CAM-ICU) on ICU day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day5</measure>
    <time_frame>5 days</time_frame>
    <description>The influence of serum levels of PF4 (at ICU admission) on cognitive impairment (defined by CAM-ICU) on ICU day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers-delirium-day5</measure>
    <time_frame>5 days</time_frame>
    <description>The influence of serum levels of lactate (at ICU admission) on cognitive impairment (defined by CAM-ICU) on ICU day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers2-delirium-2</measure>
    <time_frame>2 days</time_frame>
    <description>The influence of serum levels of CRP (on day 2) on cognitive impairment (defined by CAM-ICU) on ICU day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers2-delirium-2</measure>
    <time_frame>2 days</time_frame>
    <description>The influence of serum levels of TNF-alpha (on day 2) on cognitive impairment (defined by CAM-ICU) on ICU day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers2-delirium-2</measure>
    <time_frame>2 days</time_frame>
    <description>The influence of serum levels of HMGB1 (on day 2) on cognitive impairment (defined by CAM-ICU) on ICU day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers2-delirium-2</measure>
    <time_frame>2 days</time_frame>
    <description>The influence of serum levels of lactate (on day 2) on cognitive impairment (defined by CAM-ICU) on ICU day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers2-delirium-2</measure>
    <time_frame>2 days</time_frame>
    <description>The influence of serum levels of PF4 (on day 2) on cognitive impairment (defined by CAM-ICU) on ICU day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers2-delirium-5</measure>
    <time_frame>5 days</time_frame>
    <description>The influence of serum levels of CRP (on day 2) on cognitive impairment (defined by CAM-ICU) on ICU day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers5-delirium-5</measure>
    <time_frame>5 days</time_frame>
    <description>The influence of serum levels of TNF-alpha (on day 5) on cognitive impairment (defined by CAM-ICU) on ICU day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers5-delirium-5</measure>
    <time_frame>5 days</time_frame>
    <description>The influence of serum levels of HMGB1 (on day 5) on cognitive impairment (defined by CAM-ICU) on ICU day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers5-delirium-5</measure>
    <time_frame>5 days</time_frame>
    <description>The influence of serum levels of PF4 (on day 5) on cognitive impairment (defined by CAM-ICU) on ICU day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers5-delirium-5</measure>
    <time_frame>5 days</time_frame>
    <description>The influence of serum levels of lactate (on day 5) on cognitive impairment (defined by CAM-ICU) on ICU day 5.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Delirium</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Study group</intervention_name>
    <description>Blood samples will be taken from ICU patients on the day of ICU admission, day 2 and day 5 after ICU admission.&#xD;
Similarly, patients will be subjected to cognitive testing (CAM-ICU) to determine the presence of delirium</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Non-ventilated, non-sedated adult patients of all genders with a planned ICU stay &gt;72 hours&#xD;
        at the CHU de Charleroi, Charleroi, Belgium between October 2020- May 2021 will be included&#xD;
        in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-ventilated, non-sedated adult patients with a planned ICU stay &gt;72 hours. - -&#xD;
             patients admitted due to an exacerbation of COPD&#xD;
&#xD;
          -  patients admitted due to severe trauma&#xD;
&#xD;
          -  patients admitted due to cardiogenic shock&#xD;
&#xD;
          -  patients admitted due to septic shock&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who don't understand English, French or Dutch&#xD;
&#xD;
          -  Patients who are visually/auditory impaired (without glasses/ hearing aid)&#xD;
&#xD;
          -  Patients with known neuro-psychiatric disorders&#xD;
&#xD;
          -  Patients with known recreational drug and alcohol (ab)use&#xD;
&#xD;
          -  Patients with a neurological trauma&#xD;
&#xD;
          -  Patients on ECMO&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Piagnerelli, MD; PHD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU de Charleroi, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Saxena, MD</last_name>
    <phone>+3271921211</phone>
    <email>sarah.saxena@ulb.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Piagnerelli, MD; PHD</last_name>
    <email>michael.piagnerelli@chu-charleroi.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU-Charleroi Hopital Civil Marie Curie</name>
      <address>
        <city>Charleroi</city>
        <state>Hainaut</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Saxena, MD</last_name>
      <email>sarah.saxena@ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Michael Piagnerelli, Md; PHD</last_name>
      <email>michael.piagnerelli@chu-charleroi.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <results_reference>
    <citation>Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, Speroff T, Gautam S, Bernard GR, Inouye SK. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001 Jul;29(7):1370-9.</citation>
    <PMID>11445689</PMID>
  </results_reference>
  <results_reference>
    <citation>Leslie DL, Inouye SK. The importance of delirium: economic and societal costs. J Am Geriatr Soc. 2011 Nov;59 Suppl 2:S241-3. doi: 10.1111/j.1532-5415.2011.03671.x.</citation>
    <PMID>22091567</PMID>
  </results_reference>
  <results_reference>
    <citation>Rouhiainen A, Imai S, Rauvala H, Parkkinen J. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost. 2000 Dec;84(6):1087-94.</citation>
    <PMID>11154118</PMID>
  </results_reference>
  <results_reference>
    <citation>Vacas S, Degos V, Tracey KJ, Maze M. High-mobility group box 1 protein initiates postoperative cognitive decline by engaging bone marrow-derived macrophages. Anesthesiology. 2014 May;120(5):1160-7. doi: 10.1097/ALN.0000000000000045.</citation>
    <PMID>24162463</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu J, Feng X, Valdearcos M, Lutrin D, Uchida Y, Koliwad SK, Maze M. Interleukin-6 is both necessary and sufficient to produce perioperative neurocognitive disorder in mice. Br J Anaesth. 2018 Mar;120(3):537-545. doi: 10.1016/j.bja.2017.11.096. Epub 2018 Feb 3.</citation>
    <PMID>29452810</PMID>
  </results_reference>
  <results_reference>
    <citation>Terrando N, Eriksson LI, Ryu JK, Yang T, Monaco C, Feldmann M, Jonsson Fagerlund M, Charo IF, Akassoglou K, Maze M. Resolving postoperative neuroinflammation and cognitive decline. Ann Neurol. 2011 Dec;70(6):986-995. doi: 10.1002/ana.22664.</citation>
    <PMID>22190370</PMID>
  </results_reference>
  <results_reference>
    <citation>Cibelli M, Fidalgo AR, Terrando N, Ma D, Monaco C, Feldmann M, Takata M, Lever IJ, Nanchahal J, Fanselow MS, Maze M. Role of interleukin-1beta in postoperative cognitive dysfunction. Ann Neurol. 2010 Sep;68(3):360-8. doi: 10.1002/ana.22082.</citation>
    <PMID>20818791</PMID>
  </results_reference>
  <results_reference>
    <citation>Feng X, Valdearcos M, Uchida Y, Lutrin D, Maze M, Koliwad SK. Microglia mediate postoperative hippocampal inflammation and cognitive decline in mice. JCI Insight. 2017 Apr 6;2(7):e91229. doi: 10.1172/jci.insight.91229.</citation>
    <PMID>28405620</PMID>
  </results_reference>
  <results_reference>
    <citation>Saxena S, Lai IK, Li R, Maze M. Neuroinflammation is a putative target for the prevention and treatment of perioperative neurocognitive disorders. Br Med Bull. 2019 Jun 19;130(1):125-135. doi: 10.1093/bmb/ldz010. Review.</citation>
    <PMID>31049563</PMID>
  </results_reference>
  <results_reference>
    <citation>Ishihara T, Yoshida M, Arita M. Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis. Int Immunol. 2019 Aug 23;31(9):559-567. doi: 10.1093/intimm/dxz001. Review.</citation>
    <PMID>30772915</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang T, Xu G, Newton PT, Chagin AS, Mkrtchian S, Carlström M, Zhang XM, Harris RA, Cooter M, Berger M, Maddipati KR, Akassoglou K, Terrando N. Maresin 1 attenuates neuroinflammation in a mouse model of perioperative neurocognitive disorders. Br J Anaesth. 2019 Mar;122(3):350-360. doi: 10.1016/j.bja.2018.10.062. Epub 2018 Dec 28.</citation>
    <PMID>30770053</PMID>
  </results_reference>
  <results_reference>
    <citation>Terrando N, Gómez-Galán M, Yang T, Carlström M, Gustavsson D, Harding RE, Lindskog M, Eriksson LI. Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline. FASEB J. 2013 Sep;27(9):3564-71. doi: 10.1096/fj.13-230276. Epub 2013 May 24.</citation>
    <PMID>23709617</PMID>
  </results_reference>
  <results_reference>
    <citation>Naghibi T, Shafigh N, Mazloomzadeh S. Role of omega-3 fatty acids in the prevention of delirium in mechanically ventilated patients. J Res Med Sci. 2020 Jan 20;25:10. doi: 10.4103/jrms.JRMS_567_18. eCollection 2020.</citation>
    <PMID>32055250</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université Libre de Bruxelles</investigator_affiliation>
    <investigator_full_name>Sarah Saxena</investigator_full_name>
    <investigator_title>Anesthesiologist, principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will be made available, anonymously, if needed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

